KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to 15.12%.

  • Travere Therapeutics' EBIT Margin rose 1043900.0% to 15.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.91%, marking a year-over-year increase of 1547200.0%. This contributed to the annual value of 138.88% for FY2024, which is 1283700.0% up from last year.
  • Per Travere Therapeutics' latest filing, its EBIT Margin stood at 15.12% for Q3 2025, which was up 1043900.0% from 11.05% recorded in Q2 2025.
  • Travere Therapeutics' EBIT Margin's 5-year high stood at 53.62% during Q4 2021, with a 5-year trough of 336.53% in Q1 2024.
  • Moreover, its 5-year median value for EBIT Margin was 125.11% (2024), whereas its average is 164.08%.
  • As far as peak fluctuations go, Travere Therapeutics' EBIT Margin skyrocketed by 2861500bps in 2021, and later crashed by -3491400bps in 2022.
  • Quarter analysis of 5 years shows Travere Therapeutics' EBIT Margin stood at 53.62% in 2021, then plummeted by -651bps to 295.52% in 2022, then grew by 29bps to 209.13% in 2023, then surged by 61bps to 81.21% in 2024, then skyrocketed by 119bps to 15.12% in 2025.
  • Its EBIT Margin was 15.12% in Q3 2025, compared to 11.05% in Q2 2025 and 52.21% in Q1 2025.